IMMUNOLOGY2026™ Conference Recordings For Attendees-A novel double-stranded RNA adjuvant markedly amplifies the immunogenicity of nucleoside-modified mRNA-LNP vaccines

A novel double-stranded RNA adjuvant markedly amplifies the immunogenicity of nucleoside-modified mRNA-LNP vaccines

Video Transcription

Video Summary

The speaker described research on adding a controlled double-stranded RNA adjuvant to mRNA-LNP influenza vaccines. The adjuvant was designed to boost innate immune signaling and improve adaptive responses without major toxicity. In animal studies, the combined HA mRNA plus dsRNA-LNP vaccine caused only minimal, temporary weight loss but produced much stronger immunity than HA alone: about 25-fold higher antibody titers after boosting, a Th1-skewed IgG2c response, increased neutralizing antibodies, stronger interferon production, and more polyfunctional CD8 T cells. Overall, the dsRNA adjuvant improved the magnitude and durability of vaccine-induced antiviral immunity.

Meta Tag

Date April 19, 2026 9:45 AM - 10:00 AM

Room 102

Session Innovations in Vaccine Adjuvants and Immune Modulation

Speaker Fernanda Coirada

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

mRNA-LNP influenza vaccine

double-stranded RNA adjuvant

innate immune signaling

Th1-skewed antibody response

polyfunctional CD8 T cells

April 19, 2026 9:45 AM - 10:00 AM

102

Innovations in Vaccine Adjuvants and Immune Modulation

Fernanda Coirada

Vaccines and Immunotherapy (VAC)

2026